Search jobs Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. (BUSINESS WIRE) Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units (“RSUs”) to be distributed to one new employee with a grant date of April 1, 2021 (the “Inducement Grants”).
The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $25.76, the fair market value on the grant date. The stock options vest over four years, with 25% vesting on the one-year anniversary of the employee’s first day of employment with the Co